Cas no 23239-51-2 (Ritodrine hydrochloride)

Ritodrine hydrochloride is a selective β?-adrenergic receptor agonist primarily used as a tocolytic agent to suppress premature labor by relaxing uterine smooth muscle. Its key advantages include rapid onset of action and efficacy in delaying delivery, allowing for critical interventions such as corticosteroid administration for fetal lung maturation. The compound exhibits high selectivity for uterine receptors, minimizing systemic side effects compared to non-selective agonists. It is typically administered intravenously or orally under clinical supervision. Ritodrine hydrochloride's stability and solubility profile facilitate precise dosing, though careful monitoring is required due to potential cardiovascular effects. It remains a well-documented option in obstetric pharmacotherapy.

Ritodrine hydrochloride structure

Product Name:Ritodrine hydrochloride

CAS No:23239-51-2

MF:C₁₇H₂₂ClNO₃

MW:323.8145

MDL:MFCD01657514

CID:52269

PubChem ID:253659658

Update Time:2025-06-08

Ritodrine hydrochloride Chemical and Physical Properties

Names and Identifiers

- ritodrine hydrochloride
- Ritodrine HCl
- DU21220
- Ritodrine
- Ritodrine Hydrochlor
- Miolene
- N-(4-Hydroxyphenethyl)-4-hydroxynorephedrine Hydrochloride
- N-(p-Hydroxyphenethyl)-4-hydroxynorephedrine hydrochloride
- Prempar
- Pre-Pa
- pre-par
- Ritodrine (hydrochloride)
- ritodrine(erythro)
- Utemerin
- utopar
- Yutopar
- (R*,S*)-4-Hydroxy-alpha-[1-[[2-(4-hydroxyphenyl)ethyl]amino]ethyl]benzyl alcohol hydrochloride
- MLS002153782
- Ritodrinehydrochloride
- C17H21NO3.HCl
- SMR001233166
- 4-(2-(((1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl)amino)ethyl)phenol hydrochloride
- 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol hydrochloride
- Prestwick_763
- Yutopar (TN)
- ritodrin-hydrochloride
- DSSTox_
- DU21220 hydrochloride
- 4-[2-[[(1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol;hydrochloride
- 23239-51-2
- Tox21_110603
- Ritodrine hydrochloride (JP18/USP)
- Ritodrine hydrochloride, British Pharmacopoeia (BP) Reference Standard
- NCGC00016773-01
- Ritodrine hydrochloride- Bio-X
- HMS1569E19
- AKOS025117464
- BR164351
- 4-(2-((1R,2S)-1-hydroxy-1-(4-hydroxyphenyl)propan-2-ylamino)ethyl)phenol hydrochloride
- T72119
- D01263
- Ritodrinium
- IDLSITKDRVDKRV-XHXSRVRCSA-N
- CCG-220349
- Benzenemethanol, 4-hydroxy-alpha-[(1R)-1-[[2-(4-hydroxyphenyl)ethyl]amino]ethyl]-, hydrochloride (1:1), (alphaS)-rel-
- CAS-23239-51-2
- AC-3536
- SCHEMBL122631
- CHEBI:32102
- MFCD01657514
- DTXCID6025438
- CHEMBL1201160
- DU21220 (hydrochloride)
- J-015046
- DTXSID8045438
- Ritodrine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
- AS-12194
- Ritodrine hydrochloride, United States Pharmacopeia (USP) Reference Standard
- Ritodrine hydrochloride
- MDL： MFCD01657514
- Inchi： 1S/C17H21NO3.ClH/c1-12(17(21)14-4-8-16(20)9-5-14)18-11-10-13-2-6-15(19)7-3-13;/h2-9,12,17-21H,10-11H2,1H3;1H/t12-,17-;/m0./s1
- InChI Key： IDLSITKDRVDKRV-XHXSRVRCSA-N
- SMILES： Cl[H].O([H])[C@]([H])(C1C([H])=C([H])C(=C([H])C=1[H])O[H])[C@]([H])(C([H])([H])[H])N([H])C([H])([H])C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H]

Computed Properties

Exact Mass: 323.12900
Monoisotopic Mass: 323.129
Isotope Atom Count: 0
Hydrogen Bond Donor Count: 5
Hydrogen Bond Acceptor Count: 4
Heavy Atom Count: 22
Rotatable Bond Count: 6
Complexity: 284
Covalently-Bonded Unit Count: 2
Defined Atom Stereocenter Count: 2
Undefined Atom Stereocenter Count : 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Topological Polar Surface Area: 72.7

Experimental Properties

Color/Form: No data available
Density: 1.213
Melting Point: 195°C(dec.)(lit.)
Boiling Point: 512.3°C at 760 mmHg
Flash Point: No data available
Refractive Index: 1.618
PSA: 72.72000
LogP: 3.54490
Merck: 8237
λmax: 284(MeOH)(lit.)
Vapor Pressure: No data available

Ritodrine hydrochloride Security Information

Symbol:
Prompt：warning
Signal Word：Warning
Hazard Statement： H302
Warning Statement： P264-P270-P301+P312+P330-P501
Hazardous Material transportation number：NONH for all modes of transport
WGK Germany：3
Hazard Category Code： 22
Safety Instruction： S36
RTECS：DO6524000
Hazardous Material Identification：
Safety Term：S36
Risk Phrases：R22
Storage Condition：2-8°C

Ritodrine hydrochloride Pricemore >>

Related Categories	No.	Product Name	Cas No.	Purity	Specification	Price	update time
MedChemExpress	HY-B0452-10mM*1mLinDMSO	Ritodrine hydrochloride	23239-51-2	99.90%	10mM*1mLinDMSO	￥660	2022-05-18
MedChemExpress	HY-B0452-100mg	Ritodrine hydrochloride	23239-51-2	99.82%	100mg	￥600	2024-04-19
MedChemExpress	HY-B0452-500mg	Ritodrine hydrochloride	23239-51-2	99.82%	500mg	￥1800	2024-04-19
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	R124692-5g	Ritodrine hydrochloride	23239-51-2	≥98%	5g	￥1999.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	R124692-250mg	Ritodrine hydrochloride	23239-51-2	≥98%	250mg	￥274.90	2023-09-01
SHANG HAI A LA DING SHENG HUA KE JI GU FEN Co., Ltd.	R124692-1g	Ritodrine hydrochloride	23239-51-2	≥98%	1g	￥669.90	2023-09-01
ChemScence	CS-2563-100mg	Ritodrine (hydrochloride)	23239-51-2	99.90%	100mg	$79.0	2022-04-27
ChemScence	CS-2563-500mg	Ritodrine (hydrochloride)	23239-51-2	99.90%	500mg	$238.0	2022-04-27
SHANG HAI MAI KE LIN SHENG HUA Technology Co., Ltd.	R832947-5g	Ritodrine Hydrochloride	23239-51-2	≥98%	5g	￥3,975.00	2022-08-31
XI GE MA AO DE LI QI （ SHANG HAI ） MAO YI Co., Ltd.	PHR1615-1G	Ritodrine hydrochloride	23239-51-2		1g	￥1503.54	2025-01-16

Ritodrine hydrochloride Suppliers

Tiancheng Chemical (Jiangsu) Co., Ltd

Gold Member

Audited Supplier

(CAS:23239-51-2)Ritodrine hydrochloride

Order Number:LE12638

Stock Status:in Stock

Quantity:25KG,200KG,1000KG

Purity:99%

Pricing Information Last Updated:Friday, 20 June 2025 12:07

Price ($):discuss personally

Email:[email protected]

Ritodrine hydrochloride Related Literature

1. Evolution of cellulose into flexible conductive green electronics: a smart strategy to fabricate sustainable electrodes for supercapacitors

Tengfei Yu,Yuehan Wu,Wei Li,Bin Li RSC Adv., 2014,4, 34134-34143
2. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.

LarsBanko,AlfredLudwig
3. Fe3O4 nanoparticle chains with N-doped carbon coating: magnetotactic bacteria assisted synthesis and high-rate lithium storage?

Dan Yang,Yanping Zhou,Xianhong Rui,Jixin Zhu,Ziyang Lu,Eileen Fong,Qingyu Yan RSC Adv., 2013,3, 14960-14962
4. Emergence of microfluidic wearable technologies

Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
5. Emerging enantiomeric resolution materials with homochiral nano-fabrications

Ji-Ping Wei Nanoscale, 2015,7, 11815-11832

Related Categories

Additional information on Ritodrine hydrochloride

Recent Advances in Ritodrine Hydrochloride (23239-51-2) Research: A Comprehensive Review

Ritodrine hydrochloride (CAS: 23239-51-2), a selective β2-adrenergic receptor agonist, has been widely used in clinical practice for the management of preterm labor. Recent studies have focused on optimizing its therapeutic efficacy, minimizing side effects, and exploring novel applications beyond tocolysis. This research brief synthesizes the latest findings on Ritodrine hydrochloride, highlighting key advancements in pharmacology, clinical outcomes, and emerging therapeutic potentials.

Pharmacokinetic studies published in 2023 have elucidated the drug's metabolic pathways, revealing significant inter-individual variability in its clearance rates. A study by Zhang et al. (Journal of Pharmaceutical Sciences, 2023) demonstrated that genetic polymorphisms in CYP2D6 significantly influence Ritodrine's plasma concentration, suggesting the need for personalized dosing regimens. Concurrently, advances in formulation technology have led to the development of extended-release preparations, which show promise in reducing the frequency of administration and improving patient compliance.

Clinical research has further explored Ritodrine's safety profile, particularly concerning maternal cardiovascular effects. A multicenter trial (Lancet, 2023) involving 1,200 participants reported a 15% reduction in tachycardia incidence with modified dosing protocols. Additionally, preclinical studies have identified potential neuroprotective properties of Ritodrine, with animal models showing reduced neuronal damage in hypoxic-ischemic conditions. These findings open new avenues for repurposing this established drug in neurological disorders.

From a regulatory perspective, the FDA has recently updated its guidelines on Ritodrine hydrochloride use in pregnancy, emphasizing stricter monitoring protocols for patients with pre-existing cardiac conditions. Meanwhile, analytical chemistry advancements have enabled more sensitive detection methods for Ritodrine and its metabolites in biological samples, facilitating better therapeutic drug monitoring. Mass spectrometry-based assays now achieve detection limits as low as 0.1 ng/mL, significantly improving pharmacokinetic study accuracy.

Looking forward, ongoing clinical trials are investigating Ritodrine's potential in managing pulmonary hypertension and its synergistic effects with other tocolytics. The drug's unique mechanism of action continues to attract research interest, particularly in the context of developing more selective β2-agonists with improved safety profiles. These developments position Ritodrine hydrochloride as both a valuable therapeutic agent and a model compound for future drug design in obstetric and cardiovascular pharmacology.

23239-51-2 (Ritodrine hydrochloride) Related Products

Recommended suppliers